All articles by GlobalData Healthcare

New screening recommendations for critical congenital heart defects

In December 2024, the American Academy of Pediatrics published an updated screening algorithm for critical congenital heart defects (CCHD). According…
AbbVie’s tavapadon achieves positive topline results in Phase III TEMPO-2 trial

On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a…
Bowel cancer cases are rising sharply in younger adult population

Bowel cancer, also known as colorectal cancer, is an aggressive cancer with a high incidence in developed countries. Only half…
Positive interim Phase IIb data shows promise of first blood-stage malaria vaccine

A recent study carried out by researchers in Burkina Faso and the UK, and published in The Lancet Infectious Diseases,…
New study highlights increasing incidence of late-onset multiple sclerosis in Italy

Multiple sclerosis (MS) is a chronic disease of the central nervous system that occurs when the immune system attacks the…

DREAM-HF trial sheds positive light on Revascor for ischemic HF

Mesoblast Limited recently announced positive Phase III trial results in the European Journal of Heart Failure. The use of Revascor…
Highest risk CLL patients may benefit from CAR T with BTK inhibitor

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi (lisocabtagene maraleucel)…
Knock-on effects of alcohol consumption during the Covid-19 pandemic in Brazil

Over the course of the Covid-19 pandemic, the drinking habits and attitudes of many were altered, leading to a rise…
ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma

At the American Society of Hematology (ASH) Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled,…
ASH 2024: Merck’s new ADC posts positive results in first-line DLBCL

At the American Society of Hematology (ASH) annual meeting on 7 December, Merck and Co. presented results from its Phase…